Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 250, 64365-64366 [2018-27059]

Download as PDF 64365 Federal Register / Vol. 83, No. 240 / Friday, December 14, 2018 / Notices 958, to the DEA Administrator, 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been delegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. Therefore, in accordance with 21 U.S.C. 958(i) and 21 CFR 1301.34(a), this is notice that on June 11, 2018, Arizona Department of Corrections, 1305 E Butte Avenue, ASPC-Florence, Florence, Arizona 85132–9221, reapplied to be registered as an importer of Pentobarbital (2270), a basic class of the controlled substance listed in schedule II. The facility intends to import the above-listed controlled substance for legitimate use. This particular controlled substance is not available for the intended legitimate use within the current domestic supply of the United States. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture this basic class of controlled substance may file comments or objections to the issuance of the proposed registration or to the authorization of this importation, and may, at the same time, file a written request for a hearing. Any such comments, objections, or hearing requests should be addressed as described above. Dated: December 4, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–27131 Filed 12–13–18; 8:45 am] BILLING CODE 4410–09–P Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on October 31, 2018, Usona Institute, 2800 Woods Hollow Road, Madison, Wisconsin 53711 applied to be registered as an importer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Usona Institute ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 14, 2019. Such persons may also file a written request for a hearing on the application on or before January 14, 2019. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement DATES: Controlled substance Drug code 5-Methoxy-N-N-dimethyltryptamine ................................................................................................................................. Dimethyltryptamine .......................................................................................................................................................... The institute plans to import the listed controlled substances for potential formulation development for substances to be used in institutesponsored research. Dated: December 4, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–27133 Filed 12–13–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE OMB Number 1117–0008] Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 250 Drug Enforcement Administration, Department of Justice. ACTION: 60-Day Notice. amozie on DSK3GDR082PROD with NOTICES1 AGENCY: The Department of Justice, Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget for SUMMARY: VerDate Sep<11>2014 16:57 Dec 13, 2018 Jkt 247001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 7431 7435 Schedule I I review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until February 12, 2019. FOR FURTHER INFORMATION CONTACT: If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Kathy L. Federico, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should E:\FR\FM\14DEN1.SGM 14DEN1 64366 Federal Register / Vol. 83, No. 240 / Friday, December 14, 2018 / Notices amozie on DSK3GDR082PROD with NOTICES1 address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information proposed to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection 1. Type of Information Collection: Extension of a currently approved collection. 2. Title of the Form/Collection: Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: DEA Form 250. The applicable component within the Department of Justice is the Drug Enforcement Administration, Diversion Control Division. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Affected public (Primary): Business or other for-profit. Affected public (Other): None. Abstract: Pursuant to 21 U.S.C. 826 and 21 CFR 1303.12(b) and 1315.32, any person who desires to use, during the next calendar year, any basic class of controlled substances listed in schedules I or II, or the List I chemicals ephedrine, pseudoephedrine, or phenylpropanolamine for purposes of manufacturing must apply on DEA Form 250 for a procurement quota for such class or List I chemical. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: The DEA estimates 344 respondents complete 3,066 DEA Form 250 applications annually, and that each form requires 0.5 hours to complete. VerDate Sep<11>2014 16:57 Dec 13, 2018 Jkt 247001 6. An estimate of the total public burden (in hours) associated with the proposed collection: The DEA estimates this collection takes a total of 1,533 annual burden hours. If additional information is required, please contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC 20530. Dated: December 10, 2018. Melody Braswell, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2018–27059 Filed 12–13–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Overview of This Information Collection: [OMB Number 1117–0029] Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Annual Reporting Requirement for Manufacturers of Listed Chemicals Drug Enforcement Administration, Department of Justice. ACTION: 60-Day Notice. AGENCY: The Department of Justice, Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until February 12, 2019. FOR FURTHER INFORMATION CONTACT: If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Kathy L. Federico, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the SUMMARY: PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information proposed to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. 1. Type of Information Collection: Extension of a currently approved collection. 2. Title of the Form/Collection: Annual Reporting Requirement for Manufacturers of Listed Chemicals. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: Form number: N/A. The applicable component within the Department of Justice is the Drug Enforcement Administration, Diversion Control Division. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Affected public (Primary): Business or other for-profit. Affected public (Other): None. Abstract: Pursuant to 21 U.S.C. 830(b)(2) and 21 CFR 1310.05(d), manufacturers of listed chemicals must file annual reports of manufacturing, inventory, and use data for the listed chemicals they manufacture. These reports allow the DEA to monitor the volume and availability of domestically manufactured listed chemicals, which may be subject to diversion for the illicit production of controlled substances. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: Each respondent for this information collection completes one response per year. The DEA estimates there are 50 respondents, and that each response takes 0.25 hours to complete. 6. An estimate of the total public burden (in hours) associated with the proposed collection: The DEA estimates this collection takes a total of 12.5 annual burden hours. E:\FR\FM\14DEN1.SGM 14DEN1

Agencies

[Federal Register Volume 83, Number 240 (Friday, December 14, 2018)]
[Notices]
[Pages 64365-64366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27059]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

OMB Number 1117-0008]


Agency Information Collection Activities; Proposed eCollection, 
eComments Requested; Extension Without Change of a Previously Approved 
Collection; Application for Procurement Quota for Controlled Substance 
and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 
250

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: 60-Day Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Justice, Drug Enforcement Administration 
(DEA), will be submitting the following information collection request 
to the Office of Management and Budget for review and approval in 
accordance with the Paperwork Reduction Act of 1995.

DATES: Comments are encouraged and will be accepted for 60 days until 
February 12, 2019.

FOR FURTHER INFORMATION CONTACT: If you have comments, especially on 
the estimated public burden or associated response time, suggestions, 
or need a copy of the proposed information collection instrument with 
instructions or additional information, please contact Kathy L. 
Federico, Diversion Control Division, Drug Enforcement Administration; 
Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; 
Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the 
public and affected agencies concerning the proposed collection of 
information are encouraged. Your comments should

[[Page 64366]]

address one or more of the following four points:

--Evaluate whether the proposed collection of information is necessary 
for the proper performance of the functions of the agency, including 
whether the information will have practical utility;
--Evaluate the accuracy of the agency's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used;
--Evaluate whether and if so how the quality, utility, and clarity of 
the information proposed to be collected can be enhanced; and
--Minimize the burden of the collection of information on those who are 
to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submission of responses.

Overview of This Information Collection

    1. Type of Information Collection: Extension of a currently 
approved collection.
    2. Title of the Form/Collection: Application for Procurement Quota 
for Controlled Substance and for Ephedrine, Pseudoephedrine, and 
Phenylpropanolamine.
    3. The agency form number, if any, and the applicable component of 
the Department sponsoring the collection: DEA Form 250. The applicable 
component within the Department of Justice is the Drug Enforcement 
Administration, Diversion Control Division.
    4. Affected public who will be asked or required to respond, as 
well as a brief abstract:
    Affected public (Primary): Business or other for-profit.
    Affected public (Other): None.
    Abstract: Pursuant to 21 U.S.C. 826 and 21 CFR 1303.12(b) and 
1315.32, any person who desires to use, during the next calendar year, 
any basic class of controlled substances listed in schedules I or II, 
or the List I chemicals ephedrine, pseudoephedrine, or 
phenylpropanolamine for purposes of manufacturing must apply on DEA 
Form 250 for a procurement quota for such class or List I chemical.
    5. An estimate of the total number of respondents and the amount of 
time estimated for an average respondent to respond: The DEA estimates 
344 respondents complete 3,066 DEA Form 250 applications annually, and 
that each form requires 0.5 hours to complete.
    6. An estimate of the total public burden (in hours) associated 
with the proposed collection: The DEA estimates this collection takes a 
total of 1,533 annual burden hours.
    If additional information is required, please contact: Melody 
Braswell, Department Clearance Officer, United States Department of 
Justice, Justice Management Division, Policy and Planning Staff, Two 
Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC 
20530.

    Dated: December 10, 2018.
Melody Braswell,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2018-27059 Filed 12-13-18; 8:45 am]
BILLING CODE 4410-09-P